The new england journal of medicine n engl j med 352;24 www.nejm.org june 16, 2005 The diagnosis of chronic stable angina pectoris includes predictable and reproducible left anterior chest discomfort after physical activity, emotional stress, or both; symptoms are typically worse in cold weather or after meals and are relieved by rest or sublingual nitroglycerin. The presence of one or more obstructions in major coronary arteries is likely; the severity of stenosis is usually greater than 70 percent.
The diagnosis of chronic stable angina pectoris includes predictable and reproducible left anterior chest discomfort after physical activity, emotional stress, or both; symptoms are typically worse in cold weather or after meals and are relieved by rest or sublingual nitroglycerin. The presence of one or more obstructions in major coronary arteries is likely; the severity of stenosis is usually greater than 70 percent.
pathophysiology
Angina occurs when there is regional myocardial ischemia caused by inadequate coronary perfusion and is usually but not always induced by increases in myocardial oxygen requirements. Cardinal features of chronic stable angina include complete reversibility of the symptoms and repetitiveness of the anginal attacks over time, typically months to years. New, prolonged, or recent-onset symptoms are characteristic of unstable angina. Coexisting conditions, such as poorly controlled hypertension, anemia, or thyrotoxicosis, can precipitate or accentuate angina.
As coronary atherosclerosis progresses, there is deposition of plaque external to the lumen of the artery; the plaque may extend eccentrically and outward without compromising the lumen (Fig. 1) . Thus, stress testing or angiography may not suggest coronary disease, even in the presence of significant atherosclerosis. As atherosclerosis worsens, encroachment of the plaque mass into the lumen can result in hemodynamic obstruction and angina 1 (Fig. 1) . Disordered endothelial vasomotor function of the coronary arteries is common in patients with angina and results in diminished vasodilatation or even vasoconstriction in response to various stimuli, including exercise. 5, 6 Occasionally, patients with severe aortic-valve disease or hypertrophic cardiomyopathy have anginalike chest pain in the absence of overt coronary disease. ducible ischemia and a reduced coronary flow reserve yet no significant obstruction on coronary angiography. 9,10, 13 Atypical presentations of angina are also more frequent in older patients (who often have exertional dyspnea, weakness, or sweating) than in younger patients and in patients with diabetes (who often have atypical or even silent ischemic episodes) than in those without diabetes; a high level of suspicion for coronary disease is needed in these groups. The severity of angina should be assessed to aid in management decisions (Table 2) . However, there is no direct correlation between the class of angina and the severity of coronary artery disease as determined on angiography. 7
diagnostic strategies

Stress Testing
Various diagnostic tests are available for the evaluation of suspected coronary disease. 14 Previous Clinical Practice articles in the Journal have focused on noninvasive testing for coronary artery disease. 15, 16 Table 3 summarizes common stress-testing methods. Adults with typical or atypical features of chest pain, especially those with major risk factors for coronary artery disease, should undergo stress testing. False positive and false negative exercise tests occur in up to 20 to 30 percent of persons (more commonly in women); coronary angiography is often necessary to resolve equivocal test results. Noninvasive testing may provide useful additional prognostic information, such as total exercise time, the inducibility of left ventricular dysfunction, blood-pressure and heart-rate responses, and, most important, the degree of myocardial ischemia. [14] [15] [16] In general, poor aerobic performance and disordered heart-rate or blood-pressure responses increase the likelihood of subsequent clinical events.
Coronary Angiography
Coronary angiography remains the diagnostic gold standard for obstructive coronary artery disease, but it may miss extraluminal plaque related to coronary remodeling 1 (Fig. 1) . Indications for angiography include poorly controlled symptoms; abnormal results on stress testing, particularly with a substantial burden of ischemia (e.g., 1 mm or more of ST-segment depression); ischemia at a low workload (below 5 to 6 metabolic equivalents); large, inducible single or multiple wall-motion abnormalities; and substantial nuclear-perfusion defects. Atypical chest pain or inconclusive or discordant test results occasionally warrant the use of angiography. Intermediate-grade coronary obstructions (e.g., 50 to 70 percent stenosis) may require additional evaluation, such as assessment of coronary flow reserve. Suspected vasospastic or microvascular angina requires additional specialized testing.
Cardiac Biomarkers
Elevated levels of high-sensitivity C-reactive protein 17 Involves chest wall; is positional, tender to palpation; can be inframammary; radiation patterns highly variable stabilization of plaque, or to do both is a newer concept (Table 5) , [19] [20] [21] and these forms of treatment are underprescribed.
Antianginal Agents
All antianginal drugs -nitrates, beta-adrenergic blockers, and calcium-channel blockers -have been shown to prolong the duration of exercise before the onset of angina and ST-segment depression as well as to decrease the frequency of angina. [22] [23] [24] Treadmill performance typically increases by 30 to 60 seconds with antianginal drugs as compared with performance with placebo. However, none of these agents have been shown to prevent myocardial infarction or death from coronary disease in patients being treated specifically for chronic stable angina. Head-to-head comparative trials have not demonstrated that any single class of drugs has greater antianginal efficacy than the others. 22-24 Thus, it is reasonable to begin therapy with agents from any of the three groups.
Beta-blockers work primarily by decreasing myocardial oxygen consumption through reductions in heart rate, blood pressure, and myocardial contractility. Although beta-blockers have not been shown to reduce the rate of coronary events or mortality specifically in patients with chronic stable angina, they are identified as class I drugs (i.e., there is evidence or general agreement that they are useful and effective), according to the 2002 American College of Cardiology-American Heart Association guidelines for the management of stable angina. 24 This classification is based on older trials showing that these agents prolong survival after myocardial infarction and on recent data showing that they have a similar benefit after primary angioplasty for acute non-ST-elevation myocardial infarction. 25 There have been no large trials assessing the effects of beta-blockers on survival or on rates of coronary events in patients with chronic stable angina. The side effects associated with betablockers (Table 4) are often overemphasized; these drugs can be used effectively in many patients with chronic obstructive pulmonary disease or peripheral vascular disease. 26 Calcium antagonists dilate coronary and systemic arteries, increase coronary blood flow, and decrease myocardial oxygen consumption. Although the safety of long-acting calcium-channel blockers has been questioned, data from ALLHAT (the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial) 27 and the results of a recent meta-analysis by the Blood Pressure Lowering Treatment Trialists' Collaboration 28 indicate that the use of these drugs for hypertension does not increase morbidity or mortality.
Nitrates dilate systemic and coronary arteries, including some coronary stenoses, and particularly the systemic veins; venous pooling of blood decreases cardiac work and chamber size. Sublingual or oral spray nitroglycerin relieves acute episodes of angina within 5 to 10 minutes; prophylactic use before activity can be helpful in persons with frequent angina. Whereas long-acting nitrates decrease angina and prolong exercise performance, experimental data and data from catheterization laboratories suggest that nitrates increase vascular oxidative stress and may induce paradoxical coronary arterial vasoconstriction. 29 Both appear to contribute to the development of nitrate tolerance. 30, 31 Prevention of tolerance requires an intermittent dosing strategy, with a nitrate-free interval of 12 to 14 hours (Table 4). Phosphodiesterase type 5 inhibitors (e.g., sildenafil, vardenafil, and tadalafil) and nitrates should not be used within 24 hours of one another because of the potential for serious hypotension.
Combination Therapy
Underdosing with antianginal agents is common. Even when the dosage is appropriate, physicians should anticipate the need for treatment with two or three agents in many patients. 22, 24 Certain drug combinations are recommended, and others should be avoided because of potential hypotension or bradycardia (Table 4) . Data from randomized clin-ical trials support the efficacy of combined therapy with two drugs but provide less support for the use of three agents together.
Vasculoprotective Therapy
There is considerable evidence that lifestyle changes and pharmacologic therapy may reduce the progression of atherosclerosis, stabilize plaque, or both in chronic stable angina. 19, 21, 24, 32 Aggressive interventions are warranted to control all cardiovascular risk factors, including diabetes and hypertension (a target blood pressure of ≤130/80 mm Hg is appropriate for both conditions) in persons with coronary artery disease.
* Estimates of sensitivity and specificity are derived from multiple databases and from the chronic stable angina guidelines of the American College of Cardiology and the American Heart Association. 26 The sensitivity, specificity, and predictive accuracy of all noninvasive stress-testing methods are influenced by age, sex, degree of coronary atherosclerosis, and, most important, the likelihood of coronary artery disease in the patient being tested. ECG denotes electrocardiogram, and SPECT single-photon-emission computed tomography. 
Lifestyle Changes
Regular exercise reduces the frequency of anginal symptoms, increases functional capacity, and improves endothelial function. 24, 33 Patients with chronic stable angina who are receiving medical therapy should exercise regularly, beginning at low levels for 20 to 30 minutes and increasing as symptoms allow. A recent randomized trial that compared the effects of daily exercise with those of angioplasty and stenting among patients with chronic stable angina and single-vessel coronary artery disease demonstrated better outcomes (in terms of major adverse events and improved exercise capacity) at one year in the exercise group than in the revascularization group. 34 Although dietary modification has not been studied specifically in patients with chronic stable angina, in a trial involving patients with a history of myocardial infarction who had been randomly assigned to follow either a Mediterranean diet or a prudent Western diet, the rate of cardiovascular events was 47 percent lower in the Mediterranean-diet group than in the Western-diet group, and this difference persisted for four years. 35 Trials involving multifactorial risk modification, including exercise, a low-fat diet, and smoking cessation, have demonstrated improvements in the progression of angina and coronary disease. 36 Vigorous efforts at smoking cessation and weight control are mandatory in patients with chronic stable angina. For patients with diabetes, a multifactorial approach that includes lifestyle changes and medications for glycemic control and coronary risk factors substantially reduces the risk of cardiovascular events. 37 
Pharmacologic Therapy
The use of aspirin at a dose of 81 to 150 mg per day reduces cardiovascular morbidity and mortality by 20 to 25 percent among patients with coronary artery disease. The results of several large, randomized trials indicate that the use of statins reduces the rate of coronary events and mortality in patients with established coronary artery disease and hyperlipidemia by 25 to 35 percent. Furthermore, a 25 to 30 percent reduction in revascularization rates in the large statin trials suggests a decrease in angina during the trials. 38 A recent trial involving patients * Recommended combination therapies include a nitrate with a beta-blocker and a dihydropyridine calcium-channel blocker with a beta-blocker. The combination of a dihydropyridine calcium-channel blocker with a nitrate or the combination of a rate-slowing calcium-channel blocker with a beta-blocker is not recommended. † A nitrate-free interval of 12 to 14 hours daily is necessary. than among those treated with 10 mg daily; persistent elevations in aminotransferase levels complicated therapy in 1.2 percent of patients in the highdose group, as compared with 0.2 percent of those in the low-dose group. 39 The Adult Treatment Panel III of the National Cholesterol Education Program recently recommended target LDL cholesterol levels of 60 to 70 mg per deciliter (1.6 to 1.8 mmol per liter) in high-risk patients with coronary artery disease. 40 Statins reduce the levels of C-reactive protein, and two recent studies suggest that lowering these levels is as important as decreasing LDL cholesterol levels for the optimal reduction of coronary events. 41, 42 Angiotensin-converting-enzyme (ACE) inhibitors have been reported to reduce morbidity and mortality among patients with coronary disease, 21,43 although the recent PEACE Trial (Prevention of Events with Angiotensin Converting Enzyme Inhibition Trial) did not confirm these findings, 44 possibly owing to the relatively low risk among patients in this trial as compared with those in the HOPE trial (Heart Outcomes Prevention Evaluation study) and the EUROPA study (European Trial on Reduction of Cardiac Events with Perindopril in Stable Coronary Artery Disease). 21,43 ACE inhibitors should be prescribed for patients with chronic stable angina who have a history of myocardial infarction, hypertension, left ventricular systolic dysfunction, or diabetes, as well as for patients with impaired renal function who do not have a contraindication to the use of these agents. Revascularization (performed by any technique) has not been shown to decrease the risk of myocardial infarction or death from coronary artery disease in patients with chronic stable angina and preserved left ventricular function. However, revascularization should be considered for persons with lifestyle-limiting angina who have a good medical regimen or for those with high-risk factors, such as symptomatic multivessel disease, proximal left anterior descending or left main artery disease, left ventricular systolic dysfunction, diabetes, a large ischemic bur-* LDL denotes low-density lipoprotein, MI myocardial infarction, PCI percutaneous coronary intervention, and ACE angiotensin-converting enzyme. To convert the values for cholesterol to millimoles per liter, multiply by 0.02586. 40 All recommendations in this review are consistent with those guidelines.
The diagnosis of chronic stable angina is made on the basis of anginal symptoms, a noninvasive stress test that is positive for myocardial ischemia, and documentation of coronary atherosclerosis on angiography. Antianginal drugs should be prescribed in effective doses, usually beginning with a betablocker; aspirin is mandatory. Management should routinely include lifestyle modifications, including smoking cessation, weight control, and regular exercise, and aggressive control of other cardiovascular risk factors. Drugs to slow the progression of atherosclerosis, including statins and, in many cases, ACE inhibitors, are also indicated. The target LDL cholesterol level in persons with chronic stable angina is below 100 mg per deciliter (2.6 mmol per liter); in high-risk patients, the level is 60 to 70 mg per deciliter. Angiography is generally indi-
